Silicon Valley-based Amaranth Medical has raised $20m in series B financing led by DCP Management. The Nanyang Technological University (NTU) spin-out is commercialising a bioresorbable scaffold used for treating coronary artery disease, called Fortitude. The latest round of funding will go to support development of the scaffold and an upcoming clinical trial. Existing backers Bio*One…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
